Allergan: Lost Confidence – Allergan plc (NYSE:AGN)
In a bad twist, the market perception on Allergan (AGN) has gone from bad to worse. My investment thesis was bullish on the stock in […]
AGN
End Of The Line For Synergy Pharmaceuticals – Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
No one likes to get the call wrong. Alas, it is the nature of the investment game. Reviewing our performance in 2018, our worst call […]
Synergy Pharma: What Lesson Investors Should Learn Before Moving On – Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
When it comes to biotech investing, I always focus on the science and clinical data first. Other things are secondary, such as management and marketing. […]
Viking Therapeutics Won’t Live Up To The Hype – Viking Therapeutics (NASDAQ:VKTX)
NASH – an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH – short for non-alcoholic steatohepatitis – has been a […]
What Is Bausch Health Companies Stock Worth? – Bausch Health Companies Inc. (NYSE:BHC)
After shares of Bausch Health Companies (BHC) touched close to the $28 level on three occasions since June, the stock continues to spend most of […]
Tracking John Paulson’s Paulson & Company Portfolio – Q3 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly […]
NGM Biopharmaceuticals And NASH: Making Progress – NGM Biopharmaceuticals (Pending:NGM)
Any man or institution that tries to rob me of my dignity will lose – Nelson Mandela Introduction The once dormant clinical research and development […]